Ontology highlight
ABSTRACT:
SUBMITTER: Young G
PROVIDER: S-EPMC6908828 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
Young Guy G Liesner Ri R Chang Tiffany T Sidonio Robert R Oldenburg Johannes J Jiménez-Yuste Victor V Mahlangu Johnny J Kruse-Jarres Rebecca R Wang Michael M Uguen Marianne M Doral Michelle Y MY Wright Lilyan Y LY Schmitt Christophe C Levy Gallia G GG Shima Midori M Mancuso Maria Elisa ME
Blood 20191201 24
Emicizumab, a bispecific humanized monoclonal antibody, bridges activated factor IX (FIX) and FX to restore the function of missing activated FVIII in hemophilia A. Emicizumab prophylaxis in children with hemophilia A and FVIII inhibitors was investigated in a phase 3 trial (HAVEN 2). Participants, previously receiving episodic/prophylactic bypassing agents (BPAs), were treated with subcutaneous emicizumab: 1.5 mg/kg weekly (group A), 3 mg/kg every 2 weeks (group B), or 6 mg/kg every 4 weeks (gr ...[more]